Updates

** Shares of drug developer Entrada Therapeutics TRDA.O fall 56.7% to six-month low of $6.93

** Stock on track for steepest daily percentage drop on record, if losses hold

** Co's Duchenne drug, ENTR-601-44, produced much lower increases in dystrophin, a key muscle protein, than analysts had expected in an early-to-mid stage trial

** The trial showed dystrophin levels rose by about 2.4 percentage points, far below the 10% increase William Blair analyst Myles Minter had expected in an April client note

** Entrada's drug was also well behind results from a rival drug from Avidity Biosciences

** Entrada also says children had lower exposure to the drug in their bloodstream than adults

** Co was testing the drug in ambulatory patients aged six to 17 who have a form of Duchenne caused by a specific genetic error that the treatment is designed to bypass so muscles can produce a working protein

** As of last close, stock up ~56% YTD